Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128603 | 0.90 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL4131442 | 0.83 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL5972423 | 0.81 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL4136959 | 0.80 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL4136843 | 0.80 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL4128938 | 0.79 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL4134581 | 0.79 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL4130267 | 0.79 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL6421064 | 0.77 | NR1H4 (0.59) | — | |
| SCHEMBL5674489 | 0.77 | EPHX2 (0.64) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | claimed |
| EP-2137178-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | claimed |
| WO-2008125342-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | claimed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2137178-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| WO-2008125342-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125342-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885 |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.